# Imipenem + Cilastatin Sodium

## Imipenem/Cilastatin Kabi 500/500mg inj

| TAH Drug Code      | [ITIEN](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITIEN)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Intra-abdominal, lower respiratory tract, gynecological, GUT, bone & joint, skin & soft tissue & mixed infections, endocarditis, septicemia. Prophylaxis of post-op infections.                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | Doses based on imipenem component. Administer 500 mg by IV infusion over 20-30 minutes; 1000 mg over 40-60 minutes. Adults > 70 kg and children > or = 40 kg: 1-2 g/day (250 mg Q6H, 500 mg Q8H, 1 g Q12H); severe infections: 2-4 g/day (ranges from 500 mg Q6H to 1 g Q6-8H) (maximum: 4 g/day or 50 mg/kg/day). Post-surgical infections prophylaxis in adults: 1 g IV on induction of anesthesia and 1 g 3 hours later. For high-risk surgery, 500 mg can be given at 8 and 16 hours after induction. Children (3 months and older) < 40 kg: 15 mg/kg IV Q6H (maximum: 2 g/day). |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypersensitivity to amide-type local anaesth, severe shock or heart block.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Thrombophlebitis, pain, induration, erythema & tenderness following inj. Rash, urticaria, pruritus, GI disturbances, pseudomembranous colitis, haematological disturbances, increase in liver enzymes, taste perversion. Myoclonic activity, seizures, psychic disturbances, confusional states. Dermatologic: Injection site pain Gastrointestinal: Diarrhea (1.8% ), Nausea (2% ), Vomiting (1.5% ) Hematologic: Thrombophlebitis (3.1% )                                                                                                                                          |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

